What is Nuvectis Pharma, Inc.'s stock issuance proceeds?

Nuvectis Pharma, Inc. (NVCT) reported stock issuance proceeds of $3.95M in Q4 2024.

How has Nuvectis Pharma, Inc.'s stock issuance proceeds changed year-over-year?

Nuvectis Pharma, Inc.'s stock issuance proceeds increased by 338.7% year-over-year, from $901K to $3.95M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Nuvectis Pharma, Inc. NVCT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Immix Biopharma, Inc.IMMX

$33.53K—

Relmada Therapeutics, Inc.RLMD

$160M+583%

Nuvation BioNUVB

$908K-16.1%

ImmunomeIMNM

$229K+7.5%

Arcus BiosciencesRCUS

$0-100%

Nuvalent, Inc.NUVL

$10.14M+123%

Other financials

Income statement

See full

Operating income-$6.3M-12.4%

Net income-$6.1M-13.5%

EPS (diluted)-$0.26+3.7%

Balance sheet

See full

Cash & equivalents$25.1M-15.9%

Total equity$14.2M-32.1%

Total assets$25.4M-15.8%

Cash flow

See full

Operating cash flow-$6.5M-56.0%

Valuation

See full

Market cap$739.27M+335%

Returns & leverage

See full

Return on equity-154.4%+79.4pp

Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Nuvectis Pharma, Inc.’s 10-K, filed February 25, 2025, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s stock issuance proceeds?: Nuvectis Pharma, Inc. (NVCT) reported stock issuance proceeds of $3.95M in Q4 2024.
How has Nuvectis Pharma, Inc.'s stock issuance proceeds changed year-over-year?: Nuvectis Pharma, Inc.'s stock issuance proceeds increased by 338.7% year-over-year, from $901K to $3.95M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.